IN8BIO, INC. Files Q1 2025 10-Q
Ticker: INAB · Form: 10-Q · Filed: May 7, 2025 · CIK: 1740279
| Field | Detail |
|---|---|
| Company | In8bio, Inc. (INAB) |
| Form Type | 10-Q |
| Filed Date | May 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotech, financials
TL;DR
IN8BIO Q1 2025 10-Q filed. Funding and UABRF deal details inside.
AI Summary
IN8BIO, INC. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as Incysus Therapeutics, Inc., is involved in biological products. Key financial activities and agreements, such as private placements and exclusive license agreements with UABRF, are noted within the filing.
Why It Matters
This filing provides investors with an update on IN8BIO's financial health and operational activities for the first quarter of 2025, including details on funding and strategic partnerships.
Risk Assessment
Risk Level: medium — Biotech companies often carry higher risk due to the nature of research and development, regulatory hurdles, and market volatility.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-05-07 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- IN8BIO, INC. (company) — Filer of the 10-Q
- Incysus Therapeutics, Inc. (company) — Former company name
- UABRF (company) — Party to an exclusive license agreement
- 20250331 (date) — End of reporting period
- 20250507 (date) — Filing date
FAQ
What is the primary business of IN8BIO, INC.?
IN8BIO, INC. is primarily involved in Biological Products (No Diagnostic Substances), as indicated by its Standard Industrial Classification code [2836].
When was IN8BIO, INC. previously known by another name?
The company was formerly known as Incysus Therapeutics, Inc., with a date of name change on May 10, 2018.
What is the address of IN8BIO, INC.'s principal executive offices?
The company's business address is located at Empire State Building, 350 5th Avenue, Suite 5330, New York, NY 10118.
Does the filing mention any specific agreements with other entities?
Yes, the filing mentions an 'ExclusiveLicenseAgreementMember' with 'UABRFMember' as of March 31, 2025.
What is the fiscal year end for IN8BIO, INC.?
The fiscal year end for IN8BIO, INC. is December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 regarding IN8BIO, INC. (INAB).